SEARCH

SEARCH BY CITATION

References

  • 1
    Koopman WJ, Gay S: Do nonimmunologically mediated pathways play a role in the pathogenesis of rheumatoid arthritis? Rheum Dis Clin North Am 19: 107122, 1993
  • 2
    Wofsy D, Seaman WE: Reversal of advanced murine lupus in NZB/NZW F1 mice by treatment with monoclonal antibody to L3T4. J Immunol 138: 32473253, 1987
  • 3
    Tugwell P, Pincus T, Yocum D, Stein M, Gluck O, Kraag G, McKendry R, Tesser J, Baker P, Wells G: Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med 333: 137141, 1995
  • 4
    LoBuglio AF, Wheeler RH, Trang J, Haynes A, Rogers K, Harvey EB, Sun L, Ghrayeb J, Khazaeli MB: Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci U S A 86: 42204224, 1989
  • 5
    Moreland LW, Bucy RP, Tilden A, Pratt PW, LoBuglio AF, Khazaeli M, Everson MP, Daddona P, Ghrayeb J, Kilgarriff C, Sanders ME, Koopman WJ: Use of a chimeric monoclonal anti-CD4 antibody in patients with refractory rheumatoid arthritis. Arthritis Rheum 36: 307318, 1993
  • 6
    Van der Lubbe PA, Reiter C, Breedveld FC, Krüger K, Schattenkirchner M, Sanders ME, Riethmüller G: Chimeric CD4 monoclonal antibody cM-T412 as a therapeutic approach to rheumatoid arthritis. Arthritis Rheum 36: 13751379, 1993
  • 7
    Choy EHS, Pitzalis C, Cauli A, Bijl JA, Schantz A, Woody J, Kingsley GH, Panyi GS: Percentage of anti-CD4 monoclonal antibody—coated lymphocytes in the rheumatoid joint is associated with clinical improvement: Implications for the development of immunotherapeutic dosing regimens. Arthritis Rheum 39: 5256, 1996
  • 8
    Moreland LW, Pratt PW, Mayes MD, Postlethwaite A, Weisman MH, Schnitzer T, Lightfoot R, Calabrese L, Zelinger DJ, Woody JN, Koopman WJ: Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate. Arthritis Rheum 38: 15811588, 1995
  • 9
    Van der Lubbe PA, Dijkmans BAC, Markusse HM, Nässander U, Breedveld FC: A randomized, double-blind, placebocontrolled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis. Arthritis Rheum 38: 10971106, 1995
  • 10
    Moreland LW, Pratt PW, Bucy RP, Jackson BS, Feldman JW, Koopman WJ: Treatment of refractory rheumatoid arthritis with a chimeric anti-CD4 monoclonal antibody: long-term followup of CD4+ T cell counts. Arthritis Rheum 37: 834838, 1994
  • 11
    Tak PP, van der Lubbe PA, Cauli A, Daha MR, Smeets TJM, Kluin PM, Meinders AE, Yanni G, Panayi GS, Breedveld FC: Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis. Arthritis Rheum 38: 14571465, 1995
  • 12
    Carteron NL, Wofsy D, Seaman WE: Induction of immune tolerance during administration of monoclonal antibody to L3T4 does not depend on depletion of L3T4+ cells. J Immunol 140: 713716, 1988
  • 13
    Moreland LW, Bucy RP, Knowles RW, Wacholtz MC, Haverty TP, Koopman WJ: Treating rheumatoid arthritis with a nondepleting anti-CD4 monoclonal antibody (MAb) (abstract). J Investig Med 43 (Suppl): 362A, 1995
  • 14
    Panayi GS, Choy EHS, Connolly DJA, Regan T, Manna VK, Rapson N, Kingsley GH, Johnston JM: T cell hypothesis in rheumatoid arthritis tested by humanized non-depleting anti-CD4 monoclonal antibody treatment I: suppression of disease activity and acute phase response (abstract). Arthritis Rheum 39 (Suppl 9): S244, 1996
  • 15
    Solinger AM, Yocum DE, Tesser J, Gluck O, O'Sullivan F, Henkel C, Cornett M, Lipani J: Clinical activity in an early phase I trial of PrimatizedTM IDEC-CE9.1—an anti-CD4 monoclonal antibody—in RA (abstract). Arthritis Rheum 37 (Suppl 9): S337, 1994
  • 16
    Levy R, Weisman M, Wisenhutter C, Yocum D, Schnitzer T, Goldman A, Schiff M, Breedveld F, Solinger A, MacDonald B, Lipani J: Results of a placebo-controlled, multicenter trial using a Primatized8 non-depleting anti-CD4 monoclonal antibody in the treatment of rheumatoid arthritis (abstract). Arthritis Rheum 39 (Suppl 9): S122, 1996
  • 17
    Issacs JD, Watts RA, Hazleman BL, Hale G, Keogan MT, Cobbold SP: Humanized monoclonal antibody therapy for rheumatoid arthritis. Lancet 340: 748752, 1992
  • 18
    Matteson EL, Yocum DE, St. Clair EW, Achkar AA, Thakor MS, Jacobs MR, Hays AE, Heitman CK, Johnston JM: Treatment of active refractory rheumatoid arthritis with humanized monoclonal antibody CAMPATH-1H administered by daily subcutaneous injection. Arthritis Rheum 38: 11871193, 1995
  • 19
    Weinblatt ME, Maddison PJ, Bulpitt KJ, Hazleman BL, Urowitz MB, Sturrock RD, Coblyn JS, Maier AL, Spreen WR, Manna VK, Johnston JM: CAMPATH-H1, a humanized monoclonal antibody, in refractory rheumatoid arthritis: an intravenous dose-escalation study. Arthritis Rheum 38: 15891594, 1995
  • 20
    Ruderman EM, Weinblatt ME, Thurmond LM, Pinkus GS, Gravallese EM: Synovial tissue response to treatment with CAMPATH-1H. Arthritis Rheum 38: 254258, 1995
  • 21
    Strand V, Lipsky PE, Cannon GW, Calabrese LH, Wiesenhutter C, Cohen SB, Olsen NJ, Lee ML, Lorenz TJ, Nelson B, and the CD5 Plus Rheumatoid Arthritis Investigators Group: Effects of administration of an anti-CD5 plus immunoconjugate in rheumatoid arthritis: results of two phase II studies. Arthritis Rheum 36: 620630, 1993
  • 22
    Olsen NJ, Brooks RH, Cush JJ, Lipsky PE, St. Clair EW, Matteson EL, Gold KN, Cannon GW, Jackson CG, McCune WJ, Fox DA, The Xoma RA Investigator Group, Nelson B, Lorenz T, Strand V: A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis. Arthritis Rheum 39: 11021108, 1996
  • 23
    Kirkham BW, Thien F, Pelton BK, Pitzalis C, Amlot P, Denman AM: Chimeric CD7 monoclonal antibody therapy in rheumatoid arthritis. J Rheumatol 19: 13481352, 1992
  • 24
    Kyle V, Coughlan RJ, Tighe H, Waldmann H, Hazleman BL: Beneficial effects of monoclonal antibody to interleukin-2 receptor on activated T-cells in rheumatoid arthritis. Ann Rheum Dis 48: 428429, 1989
  • 25
    Sewell KL, Parker KC, Woodworth TG, Reuben J, Swartz W, Trentham DE: DAB486IL-2 fusion toxin in refractory arthritis. Arthritis Rheum 36: 12231233, 1993
  • 26
    Moreland LW, Sewell KL, Trentham DE, Bucy RP, Sullivan WF, Schrohenloher RE, Shmerling RH, Parker KC, Swartz WG, Woodworth TG, Koopman WJ: Interleukin-2 diphtheria fusion protein (DAB486IL-2) in refractory rheumatoid arthritis: a double-blind placebo-controlled trial with open-label extension. Arthritis Rheum 38: 11771186, 1995
  • 27
    Sewell KL, Moreland LW, Furst DE, Meehan KT, Kremer JM, Rigby WFC, Parker KC, Lynch AM, Woodworth TG: Phase II open-label trial of DAB389IL-2 administered up to four times a year to patients with active rheumatoid arthritis (abstract). Arthritis Rheum 37 (Suppl 9): S341, 1994
  • 28
    Banerjee S, Haqqi TM, Luthra HS, Stuart JM, David CS: Possible role of Vβ T cell receptor genes in susceptibility to collagen-induced arthritis in mice. J Exp Med 167: 532539, 1988
  • 29
    Mor F, Lohse AW, Karin N, Cohen IR: Clinical modeling of T-cell vaccination against autoimmune disease in rats: selection of antigen-specific T-cells using a mitogen. J Clin Invest 85: 15941598, 1990
  • 30
    Rosloniec EF, Brand DD, Whittington KB, Stuart JM, Ciubotaru M, Ward ES: Vaccination with a recombinant Vα domain of a TCR prevent the development of collagen-induced arthritis. J Immunol 155: 45044511, 1995
  • 31
    Haqqi TM, Qu X-M, Anthony D, Ma J, Sy MS: Immunization with T-cell receptor Vβ chain peptides deletes pathogenic T-cells and prevents the induction of collagen-induced arthritis in mice. J Clin Invest 987: 28492858, 1996
  • 32
    Zagon G, Tumang JR, Li Y, Friedman SM, Crow MK: Increased frequency of Vβ17-positive T cells in patients with rheumatoid arthritis. Arthritis Rheum 37: 14311440, 1994
  • 33
    Goronzy JJ, Bartz-Bazzanella P, Hu W, Jendro MC, Walser-Kuntz DR, Weyand CM: Dominant clonotypes in the repertoire of peripheral CD4+ T-cells in rheumatoid arthritis. J Clin Invest 94: 20682076, 1994
  • 34
    Howell MD, Diveley JP, Lundeen KA, Esty A, Winters ST, Carlo DJ, Brostoff SW: Limited T-cell receptor B-chain heterogenity among interleukin 2 receptor-positive synovial T cells suggests a role for superantigen in rheumatoid arthritis. Proc Natl Acad Sci USA 88: 1092110925, 1991
  • 35
    Williams WV, Kieber-Emmons T, Fang Q, Von Feldt J, Wang B, Ramnujam T, Weiner DB: Conserved motifs in rheumatoid arthritis synovial tissue T-cell receptor beta chains. DNA Cell Biol 12: 425434, 1993
  • 36
    Adelman NE, Watling DL, McDevitt HO: Treatment of (NZB/NZW)F1 disease with anti-I-A monoclonal antibodies. J Exp Med 158: 13501355, 1983
  • 37
    Wooley PH, Luthra HS, Lafuse WP, Huse A, Stuart JM, David CS: Type-II collagen-induced arthritis in mice. III. Suppression of arthritis by using monoclonal and polyclonal anti-la antisera. J Immunol 134: 23662374, 1985
  • 38
    Nelson JL, Hughes KA, Smith AG, Nisperos BB, Branchaud AM, Hansen JA: Maternal-fetal disparity in HLA class II alloantigens and the pregnancy-induced amelioration of rheumatoid arthritis. N Engl J Med 329: 466471, 1993
  • 39
    Moreland LW, Heck LW, Koopman WJ, Saway PA, Adamson TC, Fronek Z, O'Connor RD, Morgan EE, Diveley JD, Richieri SP, Carlo DJ, Brostoff SW: Vβ17 T-cell receptor peptide vaccine in rheumatoid arthritis: results of phase I dose escalation study. J Rheumatol 23: 13531362, 1966
  • 40
    Van Laar JM, Miltenburg AMM, Verdonk MJA, Leow A, Elferink BG, Daha MR, Cohen IR, de Vries RR, Breedveld FC: Effects of inoculation with attenuated autologous T cells in patients with rheumatoid arthritis. J Autoimmun 6: 159167, 1993
  • 41
    Kingsley GH, Verwilghen J: T-cell vaccinations in humans. Clin Exp Rheumatol 11: S63S64, 1993
  • 42
    Lohse AW, Bakker NPM, Hermann E, Poralla T, Jonker M, Meyer ZUM, Buschenfelde KH: Induction of an anti-vaccine response by T-cell vaccination in non-human primates and humans. J Autoimmun 1: 121130, 1993
  • 43
    Combe B, Cosso B, Clot J, Bonneau M, Sany J: Human placentaeluted gammaglobulins in immunomodulating treatment of rheumatoid arthritis. Am J Med 78: 920928, 1985
  • 44
    Moynier M, Cosso B, Brochier J, Clot J: Identification of class II HLA alloantibodies in placenta-eluted gamma globulins used for treating rheumatoid arthritis. Arthritis Rheum 30: 375381, 1987
  • 45
    Fiocco U, Cozzi L, Cozzi E: Treatment of rheumatoid arthritis by murine anitiidiotypic monoclonal antibodies to a syngeneic anti-HLA class II monoclonal antibody. Br J Rheumatol 30: 9094, 1991
  • 46
    Smith JB, Fort JG: Treatment of rheumatoid arthritis by immunization with mononuclear white blood cells: results of a preliminary trial. J Rheumatol 23: 220225, 1996
  • 47
    Pratt W, Heck L, Moreland L, Koopman W, Parkhill T, Pratt G, Hanavan S, Wehner N, Holcenberg J, Winkelhake J: Safety and immunogenecity of a single intramuscular injection of a synthetic HLA-DR4/1-peptide vaccine with alum adjuvant in rheumatoid arthritis patients (abstract). Arthritis Rheum 38 (Suppl 9): S281, 1995
  • 48
    Arend WP, Dayer J-M: Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis. Arthritis Rheum 38: 151160, 1995
  • 49
    Williams RO, Mason LJ, Feldmann M, Maini RN: Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. Proc Natl Acad Sci 91: 27622766, 1994
  • 50
    Wooley PH, Whalen JD, Chapman DL, Berger AE, Richard KA, Aspar DG, Staite ND: The effect of an interleukin-1 receptor antagonist protein on type II collagen-induced arthritis and antigen-induced arthritis in mice. Arthritis Rheum 36: 13051314, 1993
  • 51
    Williams RO, Ghrayeb J, Feldman M, Maini RN: Successful therapy of collagen-induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD-4. Immunology 84: 433439, 1995
  • 52
    Wooley PH, Dutcher J, Widmer MB, Gillis S: Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. J Immunol 11: 66026607, 1993
  • 53
    Van den Berg WB, Joosten LM, Helsen M, van de Loo FA: Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment. Clin Exp Immunol 95: 237243, 1994
  • 54
    Keffer J, Probert L, Cazlaris H, Georgopoulous S, Kaslaris E, Kioussis D, Kollias G: Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 10: 40254031, 1991
  • 55
    Eliaz R, Wallach D, Kost J: Long-term protection against the effects of tumor necrosis factor by controlled delivery of the soluble p55 TNF receptor. Cytokine 8: 482487, 1996
  • 56
    Joosten LAB, Helsen MMA, van de Loo FAJ, van den Berg WB: Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFα, anti-IL-1α/β, and IL-1Ra. Arthritis Rheum 39: 797809, 1996
  • 57
    Van de Loo FAJ, Joosten LAB, van Lent PLEM, Arntz OJ, van den Berg WB: Role of interleukin-1, tumor necrosis factor α, and interleukin-6 in cartilage proteoglycan metabolism and destruction: effect of in situ blocking in murine antigen- and zymosan-induced arthritis. Arthritis Rheum 38: 164172, 1995
  • 58
    Arend WP: Interleukin-1 receptor antagonist: a new member of the interleukin family. J Clin Invest 88: 14451451, 1991
  • 59
    Campion GV, Lebsack ME, Lookabaugh J, Gordon G, Catalano M, and the IL-1Ra Arthritis Study Group: Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum 39: 10921101, 1996
  • 60
    Bresnihan B, on behalf of the collaborating investigators, Lookabaugh J, Witt K, Musikic P: Treatment with recombinant human interleukin-1 receptor antagonist (rhuIL-1ra) in rheumatoid arthritis: results of a randomized double-blind, placebo-controlled multicenter (abstract). Arthritis Rheum 39 (Suppl 9) S73, 1996
  • 61
    Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmmith C, Katz LM, Lightfoot R Jr, Paulus H, Strand V, Tugwell P, Weinblatt M, Williams HJ, Wolfe F, Kieszak S: American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38: 727735, 1995
  • 62
    Symons JA, Eastgate JA, Duff GW: Purification and characterization of a novel soluble receptor for interleukin-1. J Exp Med 174: 12511254, 1991
  • 63
    Arend WP, Malyak M, Smith MF Jr, Whisenend TD, Slack JL, Sims JE, Giri JG, Dower SK: Binding of the IL-1 alpha, IL-1 beta, and IL-1 receptor antagonist by soluble IL-1 receptors and levels of soluble IL-1 receptors by synovial fluids. J Immunol 153: 47664774, 1994
  • 64
    Drevlow B, Capezio J, Lovis R, Jacobs C, Landay A, Pope RM: Phase I study of recombinant human interleukin-1 receptor (rhu IL-1R) administered intra-articularly in active rheumatoid arthritis (abstract). Arthritis Rheum 36 (Suppl 9): S39, 1993
  • 65
    Drevlow BE, Lovis R, Haag MA, Sinacore JM, Jacobs C, Blosche C, Landay A, Moreland LW, Pope RM: Recombinant human interleukin-1 receptor type 1 in the treatment of patients with active rheumatoid arthritis. Arthritis Rheum 39: 257265, 1996
  • 66
    Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, Brennan FM, Walker J, Bijl H, Ghrayeb J, Woody JN: Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthritis Rheum 36: 16811690, 1993
  • 67
    Elliott MJ, Maini RN, Feldman M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, Macfarlane JD, Bijl H: Randomized double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344: 11051110, 1994
  • 68
    Paulus HE, Egger MJ, Ward JR, Williams HJ, and the Cooperative Systematic Studies of Rheumatic Diseases Group: Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. Arthritis Rheum 33: 477484, 1990
  • 69
    Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Bijl H, Woody JN: Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis. Lancet 344: 11251127, 1994
  • 70
    Tak PP, Taylor PC, Breedveld FC, Smeets TJM, Daha MR, Kluin PM, Meinders AE, Maini RN: Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor α monoclonal antibody treatment inpatients with rheumatoid arthritis. Arthritis Rheum 39: 10771081, 1996
  • 71
    Lorenz H-M, Antoni C, Valerius T, Repp R, Grünke M, Schwerdtner N, Nüblein H, Woody J, Kalden JR, Manger B: In vivo blockade of TNF-α by intravenous infusion of a chimeric monoclonal TNF-α antibody in patients with rheumatoid arthritis: short-term cellular and molecular effects. J Immunol 156: 16461653, 1996
  • 72
    Paleolog EM, Hunt M, Elliott MJ, Feldmann M, Maini RN, Woody JN: Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor α antibody in rheumatoid arthritis. Arthritis Rheum 39: 10821091, 1996
  • 73
    Rankin ECC, Choy EHS, Kassimos D, Kingsley GH, Sopwith AM, Isenberg DA, Panayi GS: The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol 34: 334342, 1992
  • 74
    Tartaglia LA, Weber RF, Figari IS, Reynolds C, Palladino MA Jr: The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc Natl Acad Sci U S A 88: 92929296, 1991
  • 75
    Lantz M, Bjornberg F, Olsson I, Richter J: Adherence of neutrophils induces release of soluble tumor necrosis factor receptor forms. J Immunol 152: 13621369, 1994
  • 76
    Mohler KM, Torrance DS, Smith CA, Goodwin RG, Stremler KE, Fung VP, Madani H, Widmer MB: Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 151: 15481561, 1993
  • 77
    Moreland LW, Margolies GR, Heck LW, Saway PA, Blosch C, Hanna R, Koopman WJ: Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis. J Rheumatol 23: 18491855, 1996
  • 78
    Baumgartner S, Moreland LW, Schiff MH, Tindall E, Fleischmann RM, Weaver A, Ettlinger RE, Gruber BL, Katz RS, Skosey JL, Lies RB, Robison A, Blosch C: Double-blind, placebo controlled trial of tumor necrosis factor receptor fusion protein (TNFR:Fcc) in active rheumatoid arthritis (abstract). J Invest Med 44: 235A, 1996
  • 79
    Evans RJ, McCabe JG, Bendele AM, Kieft GL, McAbee TJ, Edwards CK III: Efficacy of tumor necrosis factor binding protein (TNF-bp) in streptococcal cell wall-induced reaction model of arthritis (abstract). Arthritis Rheum 39 (Suppl 9): S284, 1996
  • 80
    Jacob CO, Holoshitz J, van der Meide P, Strober S, McDevitt HO: Heterogeneous effects of IFN-gamma in adjuvant arthritis. J Immunol 142: 15001505, 1989
  • 81
    Mauritz NJ, Holmdahl R, Jonsson R, van der Meide PH, Scheynius A, Klareskog L: Treatment with gamma-interferon triggers the onset of collagen arthritis in mice. Arthritis Rheum 31: 12971304, 1988
  • 82
    Cannon GW, Pincus SH, Emkey RD, Denes A, Cohen SA, Wolfe F, Saway PA, Jaffer AM, Weaver AL, Cogen L, Schindler JD: Double-blind trial of recombinant γ-interferon versus placebo in the treatment of rheumatoid arthritis. Arthritis Rheum 32: 964973, 1989
  • 83
    Lemmel EM, Gaus W, Hofschneider PH: Multicenter double-blind trial of interferon-γ versus placebo in the treatment of rheumatoid arthritis. Arthritis Rheum 34: 16211622, 1991
  • 84
    Veys EM, Mielants H, Verbruggen G, Grosclaude JP, Meyer W, Galazka A, Schindler J: Interferon gamma in RA: a double blind study comparing human recombinant interferon gamma with placebo. J Rheumatol 15: 570574, 1988
  • 85
    Machold KP, Neumann K, Smolen JS: Recombinant human interferon gamma in the treatment of rheumatoid arthritis: double blind placebo controlled study. Ann Rheum Dis 51: 10391043, 1992
  • 86
    Wendling D, Racadot E, Wijdenes J: Treatment of severe rheumatoid arthritis by anti-interleukin-6 monoclonal antibody. J Rheumatol 20: 259262, 1993
  • 87
    Ralph P, Nakoinz I, Sampson-Johannes A, Fong S, Lowe D, Min HY, Lin L: IL-10, T lymphocyte inhibitor of human blood cell production of IL-1 and tumor necrosis factor. J Immunol 148: 808814, 1992
  • 88
    Cassatella MA, Meda L, Bonora S, Ceska M, Constantin G: Interleukin (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes: evidence for an autocrine role of tumor necrosis factor and IL-1 beta in mediating the production of IL-8 triggered by lipopolysaccharide. J Exp Med 178: 22072211, 1993
  • 89
    Lacraz S, Nicod LP, Chicheportiche R, Welgus HG, Dayer JM: IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J Clin Invest 96: 23042310, 1995
  • 90
    Vannier E, Miller LC, Dinarello CA: Coordinated antiinflammatory effects of interleukin-4: interleukin-4 suppresses interleukin 1 production but upregulates gene expression and synthesis of interleukin-1 receptor antagonist. Proc Natl Acad Sci U S A 89: 40764080, 1992
  • 91
    Allen JB, Wong HL, Costa GL, Bienkowski MJ, Wahl SM: Suppression of monocyte function and differential regulation of IL-1 and IL-1ra by IL-4 contribute to resolution of experimental arthritis. J Immunol 151: 43444351, 1993
  • 92
    Nalger-Anderson C, Bober LA, Robinson ME, Siskind GW, Thorbecke GJ: Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen. Proc Natl Acad Sci U S A 83: 74437446, 1986
  • 93
    Zhang ZJ, Lee CSY, Lider O, Weiner HL: Suppression of adjuvant arthritis in Lewis rats by oral administration of type II collagen. J Immunol 145: 24892493, 1990
  • 94
    Weiner HL, Friedman A, Miller A, Khoury SJ, Al-Sabbagh A, Santos L, Sayegh M, Nussenblatt RB, Trentham DE, Hafler DA: Oral tolerance—immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of auto antigens. Annu Rev Immunol 12: 809837, 1994
  • 95
    Trentham DE, Dynesius-Trentham RA, Orav EJ, Combitchi D, Lorenzo C, Sewell KL, Hafler DA, Weiner HL: Effects of oral administration of type II collagen on rheumatoid arthritis. Science 261: 17271730, 1993
  • 96
    Sieper J, Kary S, Sörensen H, Alten R, Eggens U, Hüge W, Hiepe F, Kühne A, Listing J, Ulbrich N, Braun J, Zink A, Mitchison NA: Oral type II collagen treatment in early rheumatoid arthritis: a double-blind, placebo-controlled, randomized trial. Arthritis Rheum 39: 4151, 1996
  • 97
    Frenette PS, Wagner DD: Adhesion molecules—part I. N Engl J Med 334: 15261529, 1996
  • 98
    Frenette PS, Wagner DD: Adhesion molecules—part II. N Engl J Med 335: 4346, 1996
  • 99
    Jasin HE, Lightfoot E, Davis LS, Rothlein R, Faanes RB, Lipsky PE: Amelioration of antigen-induced arthritis in rabbits treated with monoclonal antibodies to leukocyte adhesion molecules. Arthritis Rheum 35: 541549, 1992
  • 100
    Barbadillo C, G-Arroyo A, Salas C, Mulero J, Sanchez-Madrid F, Andreu JL: Anti-integrin immunotherapy in rheumatoid arthritis: protective effect of anti-α4 antibody in adjuvant arthritis. Springer Semin Immunopathol 16: 427436, 1995
  • 101
    Kavanaugh AF, Davis LS, Nichols LA, Norris SH, Rothlein R, Scharschmidt LA, Lipsky PE: Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. Arthritis Rheum 37: 992999, 1994
  • 102
    Davis LS, Kavanaugh AF, Nichols LA, Lipsky PE: Induction of persistent T cell hyporesponsiveness in vivo by monoclonal antibody to ICAM-1 in patients with rheumatoid arthritis. J Immunol 154: 35253537, 1995
  • 103
    Kavanaugh A, Davis L, Nichols L, Lipsky P: Retreatment of rheumatoid arthritis patients with an anti-ICAM-1 monoclonal antibody (abstract). Arthritis Rheum (suppl 9) 38: S280, 1995
  • 104
    Roessler FJ, Allen ED, Wilson JM, Hartman JW, Davidson BL: Adenoviral-mediated gene transfer to rabbit synovium in vivo. J Clin Invest 92: 10851092, 1993
  • 105
    Bandara G, Mueller GM, Galea-Lauri J, Tindall MH, Georgescu HI, Suchaneek MK, Hung GL, Glorioso JC, Robbins PD, Evans CH: Intraarticular expression of biologically active interleukin-1 receptor antagonist protein by ex vivo gene transfer. Proc Natl Acad Sci U S A 90: 1076410768, 1993
  • 106
    Foy TM, Shepherd DM, Durie FH, Aruffo A, Ledbetter JA, Noelle RJ: In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. II. Prolonged suppression of the humoral immune response by an antibody to the ligand for CD4, gp39. J Exp Med 178: 15671575, 1993
  • 107
    Durie FH, Fava RA, Foy TM, Aruffo A, Ledbetter JA, Noelle RJ: Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science 261: 13281330, 1993
  • 108
    Durie FH, Aruffo A, Ledbetter J, Crassi KM, Green WR, Fast LD, Noelle RJ: Antibody to the ligand of CD40, gp39, blocks the occurrence of the acute and chronic forms of graft-vs-host disease. J Clin Invest 94: 13331338, 1994
  • 109
    June CH, Bluestone JA, Nadler LM, Thompson CB: The B7 and CD28 receptor families. Immunol Today 15: 321331, 1994
  • 110
    Linsley PS, Brady W, Grosmaire L, Ledbetter JA, Damle N: CTLA-4 is a second receptor for B cell activation antigen B7. J Exp Med 174: 561570, 1991
  • 111
    Finck BK, Linsley PS, Wofsy D: Treatment of murine lupus with CTLA4Ig. Science 265: 12251227, 1994
  • 112
    Knoerzer DB, Karr RW, Schwartz BD, Mengle-Gaw LJ: Collagen induced arthritis in the BB rat: prevention of disease by treatment with CTLA-4-Ig. J Clin Invest 96: 987993, 1995
  • 113
    Carmichael DF, Stricklin GP, Stuart JM: Systemic administration of TIMP in the treatment of collagen-induced arthritis in mice. Agents Actions 27: 378379, 1989
  • 114
    Clark SD, Kobayashi DK, Welgus HG: Regulation of the expression of tissue inhibitor of metalloproteinases and collagenase by retinoids and glucocorticoids in human fibroblasts. J Clin Invest 890: 12801288, 1987
  • 115
    Mulligan MS, Desrochers PE, Chinnaiyan AM, Gibbs DF, Varani J, Johnson KJ, Weiss SJ: In vivo suppression of immune complex induced alveolitis by secretory leukoproteinase inhibitor and tissue inhibitor of metalloproteinases 2. Proc Natl Acad Sci USA 90: 11523111527, 1993
  • 116
    Williams LM, Gibbons DL, Gearing A, Maini RN, Feldman M, Brennan FM: Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both p55 and p75 TNF receptor shedding and TNFα processing in RA synovial membrane cell cultures. J Clin Invest 97: 28332841, 1996
  • 117
    Gravallese EM, Handel ML, Coblyn J, Anderson RJ, Sperling RI, Karlson EW, Maier A, Ruderman EM, Formelli F, Weinblatt ME: N-[4-hydroxyphenyl] retinamide in rheumatoid arthritis: a pilot study. Arthritis Rheum 39: 10211026, 1996
  • 118
    Greenwald RA, Golub LM, Lavietes B, Ramamurthy NS, Gruber B, Laskin RS, McNamara TF: Tetracyclines inhibit human synovial collagenase in vivo and in vitro. J Rheumatol 14: 2832, 1987
  • 119
    Tilley BC, Alarcón GS, Heyse SP, Trentham DE, Neuner R, Kaplan DA, Clegg DO, Leisen JC, Buckley L, Cooper SM: Minocycline in rheumatoid arthritis: a 48-week, double-blind, placebo-controlled trial. Ann Intern Med 122: 8189, 1995
  • 120
    Kloppenburg M, Breedveld FC, Terwiel JP, Mallee C, Dijkmans BAC: Minocycline in active rheumatoid arthritis: a double-blind, placebo-controlled trial. Arthritis Rheum 37: 629636, 1994
  • 121
    Nakajima T, Aono H, Hasunuma T, Yamamoto K, Shirai T, Hirohata K, Nishioka K: Apoptosis and functional Fas antigen in rheumatoid arthritis synoviocytes. Arthritis Rheum 38: 485491, 1995
  • 122
    Hoa TTM, Hasunuma T, Aono H, Masuko K, Kobata T, Yamamoto K, Sumida T, Nishioka K: Novel mechanisms of selective apoptosis in synovial T cells of patients with rheumatoid arthritis. J Rheumatol 23: 13321337, 1996
  • 123
    Fujisawa Y, Asahara H, Okamoto K, Aono H, Hasunuma T, Kobata T, Iwakura Y, Yonehara S, Sumida T, Nishioka K: Therapeutic effect of the anti-fas antibody on arthritis in HTLV-1 tax transgenic mice. J Clin Invest 98: 271278, 1996